ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Neuroprotective potential of caffeine in a rotenone-induced Drosophila model of Parkinsonism.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A critical appraisal of structure-based virtual screening, binding free energy methods, and AI-driven molecular design across the evolving computational landscape of drug discovery.Journal of computer-aided molecular design · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological studies have consistently reported that certain lifestyle factors, such as the habitual consumption of caffeinated beverages (notably coffee), may protect against the risk of Parkinson's disease. Thus, the current research aims to further investigate the protective effects of caffeine against rotenone-induced neurotoxicity, with a view to providing new insights into the ameliorative potential of caffeine in mitigating rotenone-induced perturbations in Drosophila melanogaster. Age-synchronised adult Drosophila melanogaster (Harwich strain; 1-3 days old) were exposed throughout their lifespan to diets containing graded doses of caffeine (0 to 500 μM) and rotenone (0 to 750 μM) in a co-treatment paradigm. Locomotor performance was assessed using negative geotaxis and Rapid Iterative Negative Geotaxis (RING) assays. Biochemical analyses were performed to determine tyrosine hydroxylase (TH) activity, indices of oxidative stress (malondialdehyde and protein carbonyls), and the status of endogenous antioxidant defence systems (GST, catalase, and total thiols). There was no significant difference in mortality between the caffeine-treated and control groups (p > 0.05). Rotenone exposure produced significant motor deficits (p < 0.05), corresponding to a 25.50% reduction in performance. Basal control performance was 83.3% while the caffeine-treated group scored 100%. Concurrent caffeine treatment prevented the rotenone-associated reduction in tyrosine hydroxylase activity and significantly attenuated oxidative stress markers (MDA, total thiols, protein carbonyls) while preserving antioxidant enzyme activities (GST, catalase) (p < 0.05). In conclusion, concurrent caffeine exposure mitigated rotenone-induced motor deficits and biochemical markers of oxidative stress and dopaminergic dysfunction in Drosophila melanogaster. These results provide experimental support for a protective effect of caffeine in this model and justify further translational molecular studies.
Indexed as
Identifiers
42603183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.